Amphotericin B liposomal
Orphan Drug Cold Chain RequiredFDA Approved, EMA Approved
Description
Amphotericin B liposomal is a lipid formulation of the polyene antifungal amphotericin B. It is used for treatment of severe systemic fungal infections including fungal myositis caused by various fungi such as Aspergillus, Candida, and Mucorales species. The liposomal formulation reduces nephrotoxicity compared to conventional amphotericin B while maintaining antifungal efficacy.
Indications & Therapeutic Use
Fungal myositis, invasive aspergillosis, candidiasis, mucormycosis, cryptococcal meningitis
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Amphotericin B liposomal
| Generic Name | Amphotericin B liposomal |
| Brands | 1 brand available |
| Active Ingredient | Amphotericin B |
| Drug Class | Fungal myositis |
| Manufacturer | Gilead Sciences |
| Dosage Forms | IV infusion, 50mg vial for reconstitution |
| Medical Code | J02AA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes